141195-77-9

Basic information

• Product Name: sodium (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl] amino]-8-oxo-3-[(2S)-oxolan-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene- 2-carboxylate
• Synonyms: sodium (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl] amino]-8-oxo-3-[(2S)-oxolan-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene- 2-carboxylate;Cefovecin SodiuM
• CAS NO: 141195-77-9
• Molecular Formula: C17H18N5NaO6S2
• Molecular Weight: 0
• Product Categories: Amines, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 141195-77-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: g/cm³
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• CAS DataBase Reference: sodium (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl] amino]-8-oxo-3-[(2S)-oxolan-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene- 2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: sodium (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl] amino]-8-oxo-3-[(2S)-oxolan-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene- 2-carboxylate(141195-77-9)
• EPA Substance Registry System: sodium (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl] amino]-8-oxo-3-[(2S)-oxolan-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene- 2-carboxylate(141195-77-9)

Safety Data

• Hazardous Substances Data: 141195-77-9(Hazardous Substances Data)

Usage

Description

Sodium (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl] amino]-8-oxo-3-[(2S)-oxolan-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene2-carboxylate, also known as Cefovecin sodium, is a semi-synthetic broad-spectrum antibacterial agent from the cephalosporin class of chemotherapeutic agents. It is characterized by its unique chemical structure, which contributes to its potent antibacterial properties.

Uses

Used in Veterinary Medicine:
Cefovecin sodium is used as an antibiotic for the treatment of skin infections in dogs and cats. It is particularly effective against bacteria such as Pasturella multocida in cats and Staphylococcus intermedius/S. canis in dogs. One of the key advantages of Cefovecin sodium is its long-lasting nature, allowing for a single-dose injectable treatment, which simplifies the administration process and improves compliance.
Used in Antimicrobial Applications:
As a cephalosporin antibiotic, Cefovecin sodium is employed in the fight against various bacterial infections. Its broad-spectrum activity makes it a valuable tool in treating a wide range of bacterial infections, particularly in cases where the causative agent is unknown or when multiple bacterial species are involved.
Used in Research and Development:
Cefovecin sodium is also utilized in research and development for the study of antibiotic resistance, bacterial pathogenesis, and the development of new antimicrobial agents. Its unique chemical structure and potent antibacterial properties make it an interesting subject for further investigation and potential modification to enhance its efficacy or expand its applications.

Indications

DogsCefovecin sodium is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).CatsCefovecin sodium is indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.

Side effects

In cats, the most common effects are vomiting, diarrhea, decreased appetite, lethargy, hyperactivity or “acting strange” and inappropriate urination. In dogs, the most common adverse effects were lethargy, decreased appetite, vomiting, diarrhea, blood in feces, dehydration, and flatulence.

Safety

DogsCONVENIA administered to healthy four month old dogs at doses of 12 mg/kg (1.5 X), 36 mg/kg (4.5 X), and 60 mg/kg (7.5 X) every seven days by dorsoscapular subcutaneous injections was well-tolerated for a total of 5 doses. Vomiting and diarrhea were seen in all treatment groups, with the incidence of vomiting and the incidence and duration of diarrhea increasing in a dose-related manner. Injection site irritation and transient edema occurred with increasing frequency in a dose-related manner and with repeat injections. Two injection site reactions included a seroma over the shoulder and swelling lasting > 30 days. Dogs dosed at 36 mg/kg had a significant (p = 0.0088) increase in BUN (all means remained within the normal range) compared to the controls. One dog dosed at 60 mg/kg exhibited a glomerulopathy on histopathology, and one dog in this same group had minimal peliosis hepatis. At an exaggerated dose of 180 mg/kg (22.5X) in dogs, CONVENIA caused some injection site irritation, vocalization and edema. Edema resolved within 8-24 hours.www.zoetisus.com

InChI:InChI=1/C17H19N5O6S2.Na/c1-27-21-10(8-6-30-17(18)19-8)13(23)20-11-14(24)22-12(16(25)26)7(5-29-15(11)22)9-3-2-4-28-9;/h6,9,11,15H,2-5H2,1H3,(H2,18,19)(H,20,23)(H,25,26);/q;+1/p-1/b21-10-;/t9-,11+,15+;/m0./s1

Relevant articles and documents

AN IMPROVED PROCESS FOR THE PREPARATION OF CEFOVECIN SODIUM

The present invention relates to an improved process for the preparation of Cefovecin sodium of a Compound of Formula (1), by reacting THF Cephem Compound of Formula (6) with MAEM Compound of Formula (8).